- Home
- GOODO vs SRPT Comparison
GOODO vs SRPT Comparison
Compare GOODO & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GOODO
Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Current Price
Current Price
Company Overview
Basic Information| Metric | GOODO | SRPT |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | GOODO | SRPT |
|---|---|---|
| Price | $19.75 | $22.85 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 28 |
| Target Price | N/A | ★ $25.40 |
| AVG Volume (30 Days) | 5.4K | ★ 3.2M |
| Earning Date | N/A | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $18.36 | $10.42 |
| 52 Week High | $22.20 | $64.80 |
Technical Indicators
Market Signals| Indicator | GOODO | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 64.24 |
| Support Level | N/A | $20.61 |
| Resistance Level | $20.43 | $23.51 |
| Average True Range (ATR) | 0.30 | 1.39 |
| MACD | 0.02 | 0.45 |
| Stochastic Oscillator | 66.86 | 86.11 |
Price Performance
Historical ComparisonAbout GOODO Gladstone Commercial Corporation 6.00% Series G Cumulative Redeemable Preferred Stock par value $0.001 per share
Gladstone Commercial Corp is a real estate investment trust, which engages in investing and owning net leased industrial, commercial, and retail real property and making long-term industrial and commercial mortgage loans. Its portfolio consists of single-tenant commercial, industrial real properties, and medical properties nationwide. Its principal investment objectives are to generate income from rental properties.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.